Leukocytapheresis (LCAP) for treating refractory adult-onset Still’s disease (AOSD)

@article{Izumi2012LeukocytapheresisF,
  title={Leukocytapheresis (LCAP) for treating refractory adult-onset Still’s disease (AOSD)},
  author={Yasumori Izumi and Takahiro Mori and Makiko Matsuo and Yasushi Koga and Tadayoshi Ohno and Taiichiro Miyashita and Osamu Sasaki and Hironori Ezaki and Kiyoshi Migita},
  journal={Modern Rheumatology},
  year={2012},
  volume={22},
  pages={483-487}
}
This is the first report on the efficacy of leukocytapheresis (LCAP) in a patient with refractory systemic-type adult-onset Still’s disease (AOSD). A 17-year-old Japanese woman with AOSD who had been treated with prednisolone and cyclosporine A presented with relapse of typical systemic AOSD, including high fever, rash, and liver dysfunction. Steroid pulse therapy (methylprednisolone 500 mg/day) was performed, which failed to stabilize the disease. Therefore, LCAP (twice/week for a total of… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis

S Davı, A Consolaro, +3 authors A Martini
  • J Rheumatol
  • 2011
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Adult-onset Still disease.

  • Best practice & research. Clinical rheumatology
  • 2008
VIEW 1 EXCERPT